Aristea Therapeutics Appoints Ciara Kennedy, Ph.D. to its Board of Directors

May 8, 2019

PR Newswire, San Diego – May 8, 2019 – Aristea Therapeutics (Aristea), a clinical-stage drug development company developing novel therapies to treat serious inflammatory diseases, today announced the appointment of Ciara Kennedy, Ph.D. as an independent member of its Board of Directors.

“We are pleased to welcome Ciara to our Board. Her breadth of experience across all aspects of drug development, including deal-making and commercialization, will be of significant value as we continue to grow Aristea,” said James Mackay, President and CEO of Aristea Therapeutics. “We look forward to leveraging her expertise as we advance our lead therapeutic, RIST4721, through Phase 2.”

“Aristea is a great example of the strength, ingenuity, and entrepreneurial spirit that thrives in the San Diego biotech community,” added Dr. Kennedy. “I am excited to work with James and the accomplished team to help them build a pipeline of novel drugs with the greatest operational efficiency possible.”

Dr. Kennedy has significant expertise in developing and executing drug development and growth strategies for both small and large organizations. She has experience leading financing rounds, acquisitions, in-licensing activities, and day-to-day operations. Her work spans multiple therapeutic fields, including oncology, immunology, hepatology and infectious disease, and she has tackled all stages of drug and diagnostic development, from preclinical research through commercialization.

Currently, Dr. Kennedy serves as President and CEO of Amplyx Pharmaceuticals, Inc. Prior to Amplyx, Dr. Kennedy was COO of Lumena Pharmaceuticals, driving the development of assets licensed from Pfizer and Sanofi and securing venture capital financing. Lumena was acquired by Shire Pharmaceuticals in June 2014. Prior to Lumena, she was a senior strategist and VP of operations at Cypress Bioscience, where she played a key role in obtaining FDA approval for Savella®, a therapy for fibromyalgia. Additionally, Dr. Kennedy held several positions in the program and alliance department of Biogen Idec, managing projects spanning the drug discovery and development continuum. Dr. Kennedy received her doctorate at the Queen’s University of Belfast, Northern Ireland, and continued her research in the field of apoptotic proteases at the Sanford Burnham Prebys Medical Discovery Institute in La Jolla, California. In 2004, she became a member of the inaugural class of the Rady School of Management at University of California, San Diego, where she earned her MBA.

About Aristea Therapeutics

Aristea Therapeutics (Air-iss-tay-uh) is a clinical-stage drug development company developing novel therapies to treat serious inflammatory diseases. The Aristea team is leveraging its broad industry expertise and proven success in drug development to form synergistic partnerships and build a pipeline of novel drugs. Aristea’s lead program, RIST4721, is currently in Phase 2 clinical development. Aristea is headquartered in San Diego, CA. To learn more, please visit


Amy Conrad
Juniper Point